Covid-19 has reinforced vulnerabilities worldwide. It has threatened people’s health and well-being, shattered health systems, exacerbated poverty and inequality, limited children’s access to education, and negatively impacted economies.1 Blindfolded by their lack of knowledge about this disease, governments’ efforts to contain Covid-19 once and for all have been limited at best. Between January 2020 and October 2022, the pandemic illustrated the challenges of collective action by the global community to face common threats. These included the misuse, hoarding, and price gouging of vaccines, medical products, and equipment. The emergency, coupled with insatiable demand for these products and shortages, left supply chains vulnerable to abuse.2 Advancepurchasing agreements for products such as personal protective equipment (PPE) and Covid-19 vaccines transferred risks from suppliers to buyers, contributing to overbuying and overpaying.3 The Covax initiative, which
engaged in pooled procurement to reduce costs and ensure equitable distribution of Covid-19-related products in low- and lower middle-income countries, had a limited impact because of a lack of timely financing.